2026-2034年全球口服固體製劑契約製造市場規模、佔有率、趨勢及成長分析報告

預計口服固體製劑契約製造市場將從 2025 年的 412 億美元成長到 2034 年的 710.4 億美元，2026 年至 2034 年的複合年成長率為 6.24%。

隨著製藥公司擴大將生產外包給專業的合約研發生產機構（CDMO），口服固體製劑（OSD）契約製造市場正經歷顯著成長。片劑和膠囊仍然是最常見的給藥形式，推動持續的需求。外包能夠最佳化成本、擴大生產規模並確保符合國際監管標準。

成長要素包括專利到期後學名藥的生產、小分子藥物研發管線的擴充以及對靈活生產能力的需求。高活性原料藥（API）、連續生產和品管系統的技術進步正在提高效率。製藥公司在製劑開發和商業化生產方面越來越依賴合約研發生產機構（CDMO）。

未來前景穩健，這得益於學名藥和專科藥市場的不斷擴張。新興經濟體被列為具有成本競爭力的製造地。對自動化、數位化品管和監管合規的投資預計將加劇競爭。然而，供應鏈中斷和嚴格的監管可能會對業務營運產生影響。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球口服固體製劑契約製造市場：依產品分類

• 市場分析、洞察與預測
• 藥片
• 膠囊
• 粉末
• 顆粒
• 其他

第5章：全球口服固體製劑契約製造市場：依機制分類

• 市場分析、洞察與預測
• 即時發布
• 延遲釋放
• 控釋

第6章：全球口服固體製劑契約製造市場：依最終用途分類

• 市場分析、洞察與預測
• 主要企業
• 小型企業
• 其他

第7章 全球口服固體製劑契約製造市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Catalent Inc
  • Lonza
  • Aenova Group
  • Boehringer Ingelheim International GmbH
  • Jubilant Pharmova Limited
  • Patheon Pharma Services
  • Recipharm AB
  • Corden Pharma International
  • Siegfried Holding AG
  • Piramal Pharma Solutions
  • AbbVie Contract Manufacturing
  • Next Pharma AB

The Oral Solid Dosage Contract Manufacturing Market size is expected to reach USD 71.04 Billion in 2034 from USD 41.20 Billion (2025) growing at a CAGR of 6.24% during 2026-2034.

The oral solid dosage (OSD) contract manufacturing market has grown significantly as pharmaceutical companies outsource production to specialized contract development and manufacturing organizations (CDMOs). Tablets and capsules remain the most common drug delivery forms, driving sustained demand. Outsourcing enables cost optimization, scalability, and compliance with global regulatory standards.

Growth drivers include patent expirations leading to generic drug production, increasing small-molecule pipelines, and the need for flexible manufacturing capacity. Technological advancements in high-potency APIs, continuous manufacturing, and quality control systems enhance efficiency. Pharmaceutical firms increasingly rely on CDMOs for formulation development and commercial-scale production.

Future prospects are robust, supported by expanding generic and specialty drug markets. Emerging economies offer cost-competitive manufacturing hubs. Investment in automation, digital quality management, and regulatory compliance will strengthen competitiveness. However, supply chain disruptions and stringent regulatory scrutiny may impact operational dynamics.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Tablets
• Capsules
• Powders
• Granules
• Others

By Mechanism

• Immediate Release
• Delayed Release
• Controlled Release

By End Use

• Large Size Companies
• Medium & Small Size Companies
• Others

COMPANIES PROFILED

• Catalent Inc, Lonza, Aenova Group, Boehringer Ingelheim International GmbH, Jubilant Pharmova Limited, Patheon Pharma Services, Recipharm AB, Corden Pharma International, Siegfried Holding AG, Piramal Pharma Solutions, AbbVie Contract Manufacturing, Next Pharma AB
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Capsules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Powders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Granules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY MECHANISM 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mechanism
• 5.2. Immediate Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Delayed Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Controlled Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Large Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Medium & Small Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Mechanism
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Mechanism
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Mechanism
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Mechanism
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Mechanism
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Catalent Inc
  • 9.2.2 Lonza
  • 9.2.3 Aenova Group
  • 9.2.4 Boehringer Ingelheim International GmbH
  • 9.2.5 Jubilant Pharmova Limited
  • 9.2.6 Patheon Pharma Services
  • 9.2.7 Recipharm AB
  • 9.2.8 Corden Pharma International
  • 9.2.9 Siegfried Holding AG
  • 9.2.10 Piramal Pharma Solutions
  • 9.2.11 AbbVie Contract Manufacturing
  • 9.2.12 Next Pharma AB